Cogentin

(Benztropine)

Phase 2Small molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cogentin is one of 89 small molecule programs targeting Temporomandibular Joint Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Temporomandibular Joint DisorderActive, not recruiting

Back PainActive, not recruiting

SchizophreniaActive, not recruiting

Temporomandibular Joint DisorderPhase 2

Active, not recruiting

Back PainPhase 2

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Cogentin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

2 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 5

Zocor

OOrganon and Co

Preclinical

6 6

Depakote

Ibrance

Permax

VValeant Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia2 trials

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

Completed·NNational Institute of Mental Health (NIMH)·Phase 4·NCT00802100·21 enrolled

Anticholinergic Burden in Schizophrenia

Terminated·CCentre for Addiction and Mental Health·N/A·NCT00715377·2 enrolled

Back pain1 trial

Effect of Antidepressants on Back Pain

Completed·UUS Department of Veterans Affairs·Phase 2·NCT00018200·130 enrolled

Craving1 trial

Evaluation of Benztropine for Cocaine Craving - 2

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00000333

Temporomandibular Joint Disorder1 trial

Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)

Completed·JJohns Hopkins University·Phase 2·NCT00066937·140 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

COGENTIN

NDA NDA012015

Jan 1, 1982

COGENTIN

NDA NDA009193

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Benztropine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Benztropine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Benztropine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA012015). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cogentin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia2 trials

Back pain1 trial

Craving1 trial

Temporomandibular Joint Disorder1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News